{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:50:47Z","timestamp":1793987447057,"version":"4.8.0"},"reference-count":122,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>After the introduction of tyrosine kinase inhibitors (TKIs), the number of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic phase chronic myeloid leukemia (CP-CML) has dramatically decreased. Imatinib was the first TKI introduced into the clinical arena, predominantly used in the first-line setting. In cases of insufficient response, resistance, or intolerance, patients with CML can subsequently be treated with a second-, third-, or fourth-generation TKI. However, despite the approval of first-, second-, third-, and fourth-generation TKIs, allo-HSCT still remains indicated for a minority of patients with CML. Here, we discuss the indications in the era of TKIs through different cases representing the clinical situations for which allo-HSCT remains the best option. We also propose our transplant strategy to decrease transplant-related morbidity, particularly graft-versus-host disease, and mortality in the particular context of CML, a disease that is one of the most sensitive to immune cellular therapy, allowing the use of a combination of donor lymphocyte infusion and TKIs for posttransplant molecular progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026512","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:46:00Z","timestamp":1747064760000},"page":"357-368","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["How I approach hematopoietic stem cell transplantation for CML in a TKI world"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-8104","authenticated-orcid":false,"given":"Yves","family":"Chalandon","sequence":"first","affiliation":[{"name":"1Hematology Service, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"},{"name":"2Translational Research Center for Oncohematology, Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Simonetta","sequence":"additional","affiliation":[{"name":"1Hematology Service, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"},{"name":"2Translational Research Center for Oncohematology, Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Masouridi-Levrat","sequence":"additional","affiliation":[{"name":"1Hematology Service, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2026012211221808500_bib1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2026012211221808500_bib2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"2026012211221808500_bib3","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2026012211221808500_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbmt.2005.09.010","article-title":"Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study","volume":"12","author":"Chalandon","year":"2006","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026012211221808500_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ajh.26836","article-title":"Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor","volume":"98","author":"Bidikian","year":"2023","journal-title":"Am J Hematol"},{"issue":"11","key":"2026012211221808500_bib6","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026012211221808500_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ajh.26764","article-title":"Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: a retrospective study by the chronic malignancies working party of the EBMT","volume":"98","author":"Chalandon","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"2026012211221808500_bib8","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bjh.19448","article-title":"Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: a retrospective analysis from the Chronic Malignancies Working Party of the EBMT","volume":"204","author":"Onida","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2026012211221808500_bib9","doi-asserted-by":"crossref","first-page":"93.e1","DOI":"10.1016\/j.jtct.2023.09.019","article-title":"Graft-versus-host disease prophylaxis with post- transplantation cyclophosphamide in chronic myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation from an unrelated or mismatched related donor: a comparative study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)","volume":"30","author":"Ort\u00ed","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2026012211221808500_bib10","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.24793","article-title":"Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia","volume":"92","author":"Kondo","year":"2017","journal-title":"Am J Hematol"},{"issue":"8","key":"2026012211221808500_bib11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026012211221808500_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"24","key":"2026012211221808500_bib13","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2026012211221808500_bib14","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"2026012211221808500_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12185-024-03787-z","article-title":"Outcome of 3q26.2\/MECOM rearrangements in chronic myeloid leukemia","volume":"120","author":"Akiyama","year":"2024","journal-title":"Int J Hematol"},{"issue":"22","key":"2026012211221808500_bib16","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2026012211221808500_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"2026012211221808500_bib18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2026012211221808500_bib19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026012211221808500_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"2026012211221808500_bib21","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41375-020-0931-9","article-title":"The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia","volume":"34","author":"Pfirrmann","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2026012211221808500_bib22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","article-title":"A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"9134","key":"2026012211221808500_bib23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"20","key":"2026012211221808500_bib24","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"2026012211221808500_bib25","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"29","key":"2026012211221808500_bib26","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026012211221808500_bib27","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V80.5.1352.1352","article-title":"Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"issue":"1","key":"2026012211221808500_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2026012211221808500_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2014.12.010","article-title":"Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation","volume":"21","author":"Copelan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2026012211221808500_bib30","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"17","key":"2026012211221808500_bib31","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/blood-2012-02-409763","article-title":"Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era","volume":"119","author":"Warlick","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2026012211221808500_bib32","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/bloodadvances.2018024844","article-title":"Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia","volume":"2","author":"Chhabra","year":"2018","journal-title":"Blood Adv"},{"issue":"15","key":"2026012211221808500_bib33","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026012211221808500_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2008.07179.x","article-title":"Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2026012211221808500_bib35","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"9","key":"2026012211221808500_bib36","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"issue":"6","key":"2026012211221808500_bib37","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood.V73.6.1720.1720","article-title":"Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia","volume":"73","author":"Sullivan","year":"1989","journal-title":"Blood"},{"issue":"8375","key":"2026012211221808500_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(84)92848-4","article-title":"Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients","volume":"323","author":"Prentice","year":"1984","journal-title":"Lancet"},{"issue":"8401","key":"2026012211221808500_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0140-6736(84)92564-9","article-title":"Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)","volume":"2","author":"Waldmann","year":"1984","journal-title":"Lancet"},{"issue":"5","key":"2026012211221808500_bib40","first-page":"445","article-title":"Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants","volume":"3","author":"Martin","year":"1988","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"2026012211221808500_bib41","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"issue":"8","key":"2026012211221808500_bib42","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","article-title":"T-cell depletion of HLA-identical transplants in leukemia","volume":"78","author":"Marmont","year":"1991","journal-title":"Blood"},{"issue":"8","key":"2026012211221808500_bib43","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1702635","article-title":"Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study","volume":"26","author":"Beelen","year":"2000","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2026012211221808500_bib44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V97.2.383","article-title":"The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings","volume":"97","author":"Urbano-Ispizua","year":"2001","journal-title":"Blood"},{"issue":"12","key":"2026012211221808500_bib45","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.bbmt.2006.08.034","article-title":"T cell depleted peripheral blood stem cell allotransplantation with T cell add back for patients with hematological malignancies: effect of chronic GVHD on outcome","volume":"12","author":"Montero","year":"2006","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026012211221808500_bib46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2006-03-005769","article-title":"Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell\u2013depleted reduced-intensity transplantation","volume":"109","author":"Meyer","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2026012211221808500_bib47","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.bbmt.2006.10.028","article-title":"Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis","volume":"13","author":"Elhasid","year":"2007","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026012211221808500_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.bmt.1704754","article-title":"Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias","volume":"35","author":"Bunin","year":"2005","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"2026012211221808500_bib49","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ajh.23263","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up","volume":"87","author":"Zuckerman","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"2026012211221808500_bib50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2002-05-1615","article-title":"Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia","volume":"101","author":"Elmaagacli","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2026012211221808500_bib51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bmt.1704157","article-title":"ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)","volume":"32","author":"Zander","year":"2003","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"2026012211221808500_bib52","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"2026012211221808500_bib53","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","article-title":"Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti\u2013T-cell globulin ATG-Fresenius","volume":"117","author":"Soci\u00e9","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2026012211221808500_bib54","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","article-title":"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8299","key":"2026012211221808500_bib55","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(82)92735-0","article-title":"Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation","volume":"2","author":"Clift","year":"1982","journal-title":"Lancet"},{"issue":"8299","key":"2026012211221808500_bib56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(82)92736-2","article-title":"Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia","volume":"320","author":"Goldman","year":"1982","journal-title":"Lancet"},{"issue":"2","key":"2026012211221808500_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-104-2-155","article-title":"Marrow transplantation for the treatment of chronic myelogenous leukemia","volume":"104","author":"Thomas","year":"1986","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026012211221808500_bib58","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","article-title":"Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"issue":"7","key":"2026012211221808500_bib59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of pH1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin","volume":"300","author":"Fefer","year":"1979","journal-title":"N Engl J Med"},{"issue":"12","key":"2026012211221808500_bib60","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.bbmt.2007.08.006","article-title":"Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival","volume":"13","author":"Eapen","year":"2007","journal-title":"Biol Blood Marrow Transpl"},{"issue":"16","key":"2026012211221808500_bib61","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2026012211221808500_bib62","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-012-1650-8","article-title":"Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"92","author":"Oyekunle","year":"2013","journal-title":"Ann Hematol"},{"issue":"25","key":"2026012211221808500_bib63","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2026012211221808500_bib64","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"2026012211221808500_bib65","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"issue":"9","key":"2026012211221808500_bib66","doi-asserted-by":"crossref","first-page":"e247044","DOI":"10.6004\/jnccn.2024.7044","article-title":"Dose modifications in the management of chronic phase chronic myeloid leukemia: who, what, and when","volume":"22","author":"Oehler","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2026012211221808500_bib67","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026012211221808500_bib68","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026012211221808500_bib69","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1016\/S2352-3026(23)00173-4","article-title":"Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures","volume":"10","author":"Smit","year":"2023","journal-title":"Lancet Haematol"},{"issue":"20","key":"2026012211221808500_bib70","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2026012211221808500_bib71","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2026012211221808500_bib72","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026012211221808500_bib73","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026012211221808500_bib74","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","article-title":"First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia","volume":"26","author":"Rea","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2026012211221808500_bib75","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","volume":"14","author":"Ohanian","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2026012211221808500_bib76","first-page":"2876","article-title":"Comparison of the outcome between newly diagnosed patients in the accelerated phase and chronic phase with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors [abstract]","volume":"130","author":"Jiang","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2026012211221808500_bib77","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2018-99-113058","article-title":"First-line second generation tyrosine kinase inhibitors in newly diagnosed accelerated phase chronic myeloid leukemia patients [abstract]","volume":"132","author":"Balsat","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2026012211221808500_bib78","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2026012211221808500_bib79","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","article-title":"Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"le Coutre","year":"2012","journal-title":"Leukemia"},{"issue":"21","key":"2026012211221808500_bib80","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026012211221808500_bib81","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2026012211221808500_bib82","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2026012211221808500_bib83","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbmt.2019.10.017","article-title":"Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study","volume":"26","author":"DeFilipp","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2026012211221808500_bib84","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.29141","article-title":"Phase 1\/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"121","author":"Shimoni","year":"2015","journal-title":"Cancer"},{"issue":"20","key":"2026012211221808500_bib85","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026012211221808500_bib86","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2026012211221808500_bib87","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","article-title":"Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"107","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2026012211221808500_bib88","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41375-024-02204-y","article-title":"Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet blast phase registry","volume":"38","author":"Brioli","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"2026012211221808500_bib89","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2019.06.028","article-title":"Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT Chronic Malignancies Working Party","volume":"25","author":"Radujkovic","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026012211221808500_bib90","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-021-01106-1","article-title":"Impact of frontline treatment approach on outcomes of myeloid blast phase CML","volume":"14","author":"Saxena","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2026012211221808500_bib91","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"2026012211221808500_bib92","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","article-title":"Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1\/2 trial","volume":"9","author":"Copland","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026012211221808500_bib93","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1016\/S2352-3026(24)00250-3","article-title":"Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial","volume":"11","author":"Short","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026012211221808500_bib94","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"23","key":"2026012211221808500_bib95","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood.2023023502","article-title":"Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia","volume":"143","author":"Chalandon","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026012211221808500_bib96","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/hematology.2022000329","article-title":"Transplantation in CML in the TKI era: who, when, and how?","volume":"2022","author":"Niederwieser","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"2026012211221808500_bib97","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026012211221808500_bib98","first-page":"699","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Kr\u00f6ger","year":"2024","edition":"8th ed"},{"issue":"8","key":"2026012211221808500_bib99","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2026012211221808500_bib100","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","article-title":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation","volume":"102","author":"Rezvani","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2026012211221808500_bib101","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V91.10.3671","article-title":"Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant","volume":"91","author":"Alyea","year":"1998","journal-title":"Blood"},{"issue":"9","key":"2026012211221808500_bib102","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2013-08-523001","article-title":"Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion","volume":"123","author":"Bachireddy","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026012211221808500_bib103","doi-asserted-by":"crossref","first-page":"109992","DOI":"10.1016\/j.celrep.2021.109992","article-title":"Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy","volume":"37","author":"Bachireddy","year":"2021","journal-title":"Cell Rep"},{"key":"2026012211221808500_bib104","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/978-3-031-44080-9_59","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Falkenburg","year":"2024"},{"issue":"6","key":"2026012211221808500_bib105","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"issue":"6","key":"2026012211221808500_bib106","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1701131","article-title":"T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect","volume":"21","author":"Barrett","year":"1998","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"2026012211221808500_bib107","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2016.03.012","article-title":"Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia","volume":"22","author":"Xu","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026012211221808500_bib108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-018-3482-7","article-title":"Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"issue":"7","key":"2026012211221808500_bib109","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.bbmt.2015.03.012","article-title":"Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation: may we predict graft-versus-leukemia without graft-versus-host disease?","volume":"21","author":"Radujkovic","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026012211221808500_bib110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41409-024-02458-1","article-title":"Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation","volume":"60","author":"Mamez","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"2026012211221808500_bib111","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"2026012211221808500_bib112","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"issue":"15","key":"2026012211221808500_bib113","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease","volume":"10","author":"DeAngelo","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"30","key":"2026012211221808500_bib114","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"Hess","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026012211221808500_bib115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1705554","article-title":"Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis","volume":"39","author":"Palandri","year":"2007","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2026012211221808500_bib116","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41409-023-01975-9","article-title":"The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia","volume":"58","author":"Fernando","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026012211221808500_bib117","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3324\/haematol.2022.281386","article-title":"Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population","volume":"108","author":"Kockerols","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"2026012211221808500_bib118","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation","volume":"36","author":"Savani","year":"2005","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026012211221808500_bib119","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3109\/10428194.2014.910868","article-title":"The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?","volume":"56","author":"Zeidner","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026012211221808500_bib120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clml.2013.09.010","article-title":"A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation","volume":"14","author":"Shanavas","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026012211221808500_bib121","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.bbmt.2020.02.006","article-title":"The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era","volume":"26","author":"Schmidt","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2026012211221808500_bib122","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3324\/haematol.2013.100198","article-title":"Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT","volume":"99","author":"Chalandon","year":"2014","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/4\/357\/2497686\/blood_bld-2024-026512-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/4\/357\/2497686\/blood_bld-2024-026512-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:22:34Z","timestamp":1769098954000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/4\/357\/537234\/How-I-approach-hematopoietic-stem-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026512","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,22]]},"published":{"date-parts":[[2026,1,22]]}}}